NCT04069221View on ClinicalTrials.gov

Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 28, 2017

Primary Completion Date

May 30, 2017

Study Completion Date

May 30, 2017

Conditions
Malaria
Interventions
DRUG

Single oral dose of 800 mg OZ439

Single oral dose of 800 mg OZ439

DRUG

Single oral dose of 400 mg OZ439

Single oral dose of 400 mg OZ439

DRUG

Single oral dose of cobicistat

Single oral dose of 150 mg cobicistat

DRUG

iv infusion of [14C]-OZ439

15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439

Trial Locations (1)

9728

PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen

All Listed Sponsors
lead

Medicines for Malaria Venture

OTHER

NCT04069221 - Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study | Biotech Hunter | Biotech Hunter